Nasal Nitric Oxide Levels in Eosinophilic Esophagitis (EoE)

A Pilot Study: Nasal Nitric Oxide Levels in Eosinophilic Esophagitis.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01929824

Enrollment

Registered

2013-08-28

Start date

2013-08-31

Completion date

2019-09-25

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic Esophagitis

Keywords

dysphagia, trouble swallowing, chest pain

Brief summary

This study is aimed at understanding whether oral nitric oxide levels can be used as a non-invasive marker for the diagnosis and management of patient with eosinophilic esophagitis (EoE).

Detailed description

Nitric oxide (NO) is produced by activated eosinophils and oral NO levels are known to be elevated in asthma and eosinophilic bronchitis. The measurement of oral NO is a non-invasive,easy to perform low cost procedure that is used frequently in the diagnosis and management of asthma. The diagnosis of eosinophilic esophagitis (EoE) requires conscious sedation, an upper endoscopy with biopsy, and histologic evaluation of the biopsy specimen. This is a costly and somewhat invasive procedure. If oral NO was elevated as a result of activity of esophageal eosinophils in EoE, the measurement of oral NO may potentially be a very convenient and useful test in the evaluation and treatment of EoE. We propose a pilot study to determine if oral NO levels are elevated in patients with eosinophilic esophagitis.

Interventions

OTHEROral Nitric Oxide testing

o Oral nitric oxide is measured by a breathing test where the participant will be seated in a chair and asked to breathe out into a small hand-held instrument for about 6 seconds.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects with dysphagia and active esophageal infiltration (esophageal eosinophilic count of \>/= 15 eos/hpf) * Subjects with or without a clinical diagnosis of asthma

Exclusion criteria

* Subjects with chronic cough * Severe CAD * MI within the last 3 months * Cystic fibrosis * Tuberculosis * Chronic obstructive pulmonary disease (COPD)

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with increase in Oral Nitric Oxide levels	one year	To determine if oral NO correlates to activity of disease in EoE

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026